出血性疾病治疗市场规模、份额及成长分析（按药物类型、疾病类型、给药途径、最终用户和地区）－2025 年至 2032 年产业预测

出血性疾病治疗市场规模预计到 2023 年将达到 162.6 亿美元，从 2024 年的 176.6 亿美元增长到 2032 年的 341.7 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.6%。

由于几个关键因素，全球出血性疾病治疗市场正在经历显着成长。A型血友病 A和 B、血管性血友病等的盛行率不断上升，导致对先进治疗性介入的需求不断增加。重组凝血因子和基因疗法的发展等技术进步正在进一步推动市场扩张。儘管取得了这些进展，但挑战依然存在，包括尖端治疗费用高昂以及某些地区的治疗机会有限。北美和欧洲凭藉其完善的医疗保健基础设施和强大的研究倡议，目前占据市场主导地位。亚太地区的新兴经济体也正在经历由意识增强和医疗保健投资推动的成长。最近的发展凸显了该领域的动态性质。 2023 年 2 月，美国FDA核准了ALTUVIIIO，这是一款用于治疗A型血友病 A的First-in-Class、高长效 VIII 因子替代疗法。此外，BioMarin 报告了其用于治疗重度A型血友病 A 的基因疗法 ROCTAVIAN 的 3 期试验的积极结果。这些进展凸显了预防性和创新治疗的趋势，并将塑造出血性疾病管理的未来模式。然而，要充分享受这些医疗创新的好处，解决成本障碍和确保公平取得医疗服务仍然至关重要。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局

出血性疾病治疗市场规模（依药物类型及复合年增长率）（2025-2032）

• 市场概览
• 血浆来源的凝血因子浓缩物
• 重组凝血因子浓缩物
• 去氨加压素
• 抗纤维溶解剂
• 纤维蛋白胶
• 其他的

出血性疾病治疗市场规模（依疾病类型及复合年增长率）（2025-2032）

• 市场概览
• A型血友病A
• B型血友病
• 血管性血友病
• 肝病
• 其他的

出血性疾病治疗市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概览
• 静脉
• 皮下
• 口服

出血性疾病治疗市场规模（按最终用户和复合年增长率划分）（2025-2032）

• 市场概览
• 医院
• 诊所
• 学术机构
• 居家照护

出血性疾病治疗市场规模（依分销管道划分）及复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 零售药局
• 配药药房

出血性疾病治疗市场规模：按地区及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较比较（2022-2024 年）

主要企业简介

• AbbVie Inc.（USA）
• Bayer AG（Germany）
• Novo Nordisk A/S（Denmark）
• Pfizer Inc.（USA）
• Biogen（USA）
• CSL Behring（Australia）
• Grifols SA（Spain）
• Octapharma AG（Switzerland）
• BDI Pharma Inc.（USA）
• Sanofi（France）
• Takeda Pharmaceutical Company Limited（Japan）
• F. Hoffmann-La Roche AG（Switzerland）
• Amgen Inc.（USA）
• Baxter International Inc.（USA）
• BioMarin Pharmaceutical Inc.（USA）
• Genentech, Inc.（USA）
• Kedrion Biopharma Inc.（Italy）
• LFB SA（France）
• Kamada Ltd.（Israel）

结论和建议

Bleeding Disorders Treatment Market size was valued at USD 16.26 Billion in 2023 and is poised to grow from USD 17.66 Billion in 2024 to USD 34.17 Billion by 2032, growing at a CAGR of 8.6% during the forecast period (2025-2032).

The global market for bleeding disorders treatment is experiencing significant growth, driven by several key factors. The increasing prevalence of conditions such as hemophilia A and B, along with von Willebrand disease, has heightened the need for advanced therapeutic interventions. Technological advancements, including the development of recombinant clotting factors and gene therapies, are further propelling market expansion. Despite these advancements, challenges persist, notably the high costs associated with cutting-edge treatments and limited access in certain regions. North America and Europe currently dominate the market, attributed to their established healthcare infrastructures and robust research initiatives. Emerging economies in the Asia-Pacific region are also witnessing growth, driven by increasing awareness and healthcare investments. Recent developments highlight the dynamic nature of this field. In February 2023, the U.S. FDA approved ALTUVIIIO, a first-in-class, high-sustained factor VIII replacement therapy for hemophilia A, offering normal to near-normal factor activity levels with once-weekly dosing. Additionally, BioMarin Pharmaceutical reported positive results from a Phase 3 study of ROCTAVIAN, an investigational gene therapy for severe hemophilia A, indicating sustained efficacy over three years. These advancements underscore a trend towards prophylactic treatments and innovative therapies, shaping the future landscape of bleeding disorder management. However, addressing cost barriers and ensuring equitable access remain critical to fully realizing the benefits of these medical innovations.

Top-down and bottom-up approaches were used to estimate and validate the size of the Bleeding Disorders Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Bleeding Disorders Treatment Market Segments Analysis

Global Bleeding Disorders Treatment Market is segmented by Drug Type, Disease Type, Route of Administration, End User, Distribution Channel and region. Based on Drug Type, the market is segmented into Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Others. Based on Disease Type, the market is segmented into Hemophilia A, Hemophilia B, Von Willebrand Disease, Liver Disease and Others. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Oral. Based on End User, the market is segmented into Hospitals, Clinics, Academic Institutions and Homecare Settings. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Compounding Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Bleeding Disorders Treatment Market

The rising prevalence of bleeding disorders, such as hemophilia and von Willebrand disease (VWD), has led to an increased demand for advanced treatment options. VWD, for instance, affects up to 1% of the population, often going undiagnosed due to its variable symptoms. Technological advancements in hemostasis management, including the development of recombinant clotting factors and gene therapies, have resulted in more effective and targeted interventions. Innovations like the HemoSonic diagnostic device, which utilizes ultrasound technology to rapidly assess hemostasis, have received FDA approval for use in critical medical scenarios, enhancing patient outcomes.

Restraints in the Bleeding Disorders Treatment Market

The high costs associated with advanced treatments for bleeding disorders, such as hemophilia, present significant barriers to patient access, particularly in economically disadvantaged regions. For instance, gene therapies, while potentially curative, can cost up to $3.5 million per dose, placing a substantial financial strain on healthcare systems and patients. Additionally, regulatory complexities and lengthy approval processes hinder the swift introduction of innovative therapies. Challenges such as costly and restrictive clinical trials and outdated regulatory approval processes impede the advancement of new medical devices from research to clinical use.

Market Trends of the Bleeding Disorders Treatment Market

The increasing focus on personalized medicine aims to tailor treatments to individual patient profiles, optimizing efficacy and minimizing adverse effects. Advancements in gene therapy are emerging as transformative, with ongoing research and clinical trials showcasing the potential for curative approaches to certain bleeding disorders. Additionally, prophylactic treatments are gaining prominence, emphasizing the preventive management of bleeding episodes rather than reactive interventions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Bleeding Disorders Treatment Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Plasma-Derived Coagulation Factor Concentrates
• Recombinant Coagulation Factor Concentrates
• Desmopressin
• Antifibrinolytics
• Fibrin Sealants
• Others

Global Bleeding Disorders Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Liver Disease
• Others

Global Bleeding Disorders Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous
• Subcutaneous
• Oral

Global Bleeding Disorders Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Academic Institutions
• Homecare Settings

Global Bleeding Disorders Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Compounding Pharmacies

Global Bleeding Disorders Treatment Market Size & CAGR (2025-2032)

• North America (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BDI Pharma Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma Inc. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamada Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations